Capoten Articles
Captopril Reduces Diabetes Mortality
15 November 1993
ACE INHIBITORS POST-MI: THE PRACTICAL STUDY
15 November 1993
ADA ISSUES HYPERTENSION IN DIABETES GUIDELINES
8 November 1993
US 3rd QTR AFFECTED BY STRONG DOLLAR
1 November 1993
HOECHST CELANESE ACQUIRES US GENERICS CO
25 October 1993
CAPTOPRIL APPROVED FOR POST-MI USE
11 October 1993
TOP PEOPLE MOVING IN US PHARMA FIRMS
27 September 1993
ZESTRIL APPROVED FOR GP INITIATION
6 September 1993
RESULTS OF AIRE STUDY SHOW ACE INHIB BENEFIT
6 September 1993
US DRUGSTORE AUDIT DATA FOR JULY
6 September 1993
UK INDUSTRY CODE OF PRACTICE REVIEW
19 July 1993
ZESTRIL APPROVED FOR CHF IN USA
21 June 1993
SANOFI ALLIANCE WITH BRISTOL-MYERS SQUIBB
7 June 1993
THREE-WAY GENERIC AGREEMENT
31 May 1993
SPANISH FIRM ESTEVE INTERNATIONALIZES
10 May 1993
ACE INHIBITOR STUDY
19 April 1993
PRICE FLEXIBILITY AND THE DRUG INDUSTRY
12 April 1993
FDA PANEL ADVISES ON ACE INHIBITOR DRUGS
1 March 1993
GENTA'S JAGOTEC IN JV WITH GENSIA
22 February 1993
FIRST LAUNCH OF ROUSSEL UCLAF'S TRANDOLAPRIL
25 January 1993
GLOBAL DRUG MARKET: 30 YEARS OF GROWTH
4 January 1993
SAVE STUDY CONFIRMS ACE INHIBITOR BENEFITS
7 September 1992
UPDATE ON ISIS-4 PROGRESS
6 July 1992
CAPOTEN CUTS MORTALITY IN SAVE
27 April 1992
NITRATES: OLD DRUGS, BUT ONES WITH A FUTURE
20 April 1992
STRONG INCREASES IN 1991 AT BRISTOL-MYERS SQUIBB
20 April 1992
HUNGARY'S EGIS SEEKS STRATEGIC PARTNERSHIP
6 April 1992
HUNGARY'S EGIS SEEKS STRATEGIC PARTNERSHIP
6 April 1992
TEN YEARS OF ACE INHIBITION
23 March 1992
B-M SQUIBB GIVES HEART DRUGS FREE TO POOR
3 February 1992
B-M SQUIBB CUTS HEALTH PROGRAM DRUG PRICES
13 January 1992
EC PLENARY SESSION DECISIONS
6 January 1992
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
